Cluster analysis of quantitative parametric maps from DCE-MRI: Application in evaluating heterogeneity of tumor response to antiangiogenic treatment

Magnetic Resonance Imaging

Volumn 33, Issue 6, 2015, Pages 725-736

  Longo, Dario Livio ^a,b   Dastrù, Walter ^b   Consolino, Lorena ^b   Espak, Miklos ^c   Arigoni, Maddalena ^b   Cavallo, Federica ^b   Aime, Silvio ^b  

^a CNR   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiangiogenic; Clustering; DCE MRI; Gd complexes; Pharmacokinetic modeling; Tumor heterogeneity

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOMOTIN; GADOCOLETIC ACID; UNCLASSIFIED DRUG; CONTRAST MEDIUM; GADOLINIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; CLUSTER ANALYSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG RESPONSE; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; HISTOGRAM; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DISEASE MODEL; IMAGE ENHANCEMENT; PROCEDURES;

MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CLUSTER ANALYSIS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; GADOLINIUM; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C;

EID: 84930927735     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2015.03.005     Document Type: Article

References (56)

1. McDonald D.M., Choyke P.L. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003, 9:713-725.
2. Abdelrahim M., Konduri S., Basha R., Philip P.A., Baker C.H. Angiogenesis: an update and potential drug approaches (review). Int J Oncol 2010, 36:5-18.
3. Baluk P., Hashizume H., McDonald D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005, 15:102-111.
4. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006, 24:3293-3298.
5. Miyazaki K., Collins D.J., Walker-Samuel S., Taylor J.N., Padhani A.R., Leach M.O., et al. Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol 2008, 18:1414-1421.
6. Jonker D.J., Rosen L.S., Sawyer M.B., de Braud F., Wilding G., Sweeney C.J., et al. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol 2011, 22:1413-1419.
7. O'Connor J.P., Jackson A., Parker G.J., Roberts C., Jayson G.C. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 2012, 9:167-177.
8. Lavini C., de Jonge M.C., van de Sande M.G., Tak P.P., Nederveen A.J., Maas M. Pixel-by-pixel analysis of DCE MRI curve patterns and an illustration of its application to the imaging of the musculoskeletal system. Magn Reson Imaging 2007, 25:604-612.
9. Tofts P.S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997, 7:91-101.
10. Brix G., Semmler W., Port R., Schad L.R., Layer G., Lorenz W.J. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991, 15:621-628.
11. Yankeelov T.E., Luci J.J., Lepage M., Li R., Debusk L., Lin P.C., et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging 2005, 23:519-529.
12. Turetschek K., Preda A., Novikov V., Brasch R.C., Weinmann H.J., Wunderbaldinger P., et al. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 2004, 20:138-144.
13. Farace P., Merigo F., Fiorini S., Nicolato E., Tambalo S., Daducci A., et al. DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content. Eur J Radiol 2011, 78:52-59.
14. Preda A., Novikov V., Moglich M., Floyd E., Turetschek K., Shames D.M., et al. Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation. Eur Radiol 2005, 15:2268-2275.
15. Longmire M.R., Ogawa M., Choyke P.L., Kobayashi H. Dendrimers as high relaxivity MR contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2014, 6:155-162.
16. Cheng H.L., Wallis C., Shou Z., Farhat W.A. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights. J Magn Reson Imaging 2007, 25:137-145.
17. de Lussanet Q.G., Langereis S., Beets-Tan R.G., van Genderen M.H., Griffioen A.W., van Engelshoven J.M., et al. Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology 2005, 235:65-72.
18. Aime S., Gianolio E., Longo D., Pagliarin R., Lovazzano C., Sisti M. New insights for pursuing high relaxivity MRI agents from modelling the binding interaction of Gd(III) chelates to HSA. Chembiochem 2005, 6:818-820.
19. Avedano S., Tei L., Lombardi A., Giovenzana G.B., Aime S., Longo D., et al. Maximizing the relaxivity of HSA-bound gadolinium complexes by simultaneous optimization of rotation and water exchange. Chem Commun (Camb) 2007, 4726-4728.
20. Woods M., Botta M., Avedano S., Wang J., Sherry A.D. Towards the rational design of MRI contrast agents: a practical approach to the synthesis of gadolinium complexes that exhibit optimal water exchange. Dalton Trans 2005, 3829-3837.
21. Laurent S., Vander Elst L., Henrotte V., Muller R.N. Noncovalent binding of some new lipophilic gadolinium DTPA complexes to human serum albumin. A structure-affinity relationship. Chem Biodivers 2010, 7:2846-2855.
22. Geninatti-Crich S., Szabo I., Alberti D., Longo D., Aime S. MRI of cells and mice at 1 and 7 Tesla with Gd-targeting agents: when the low field is better!. Contrast Media Mol Imaging 2011, 6:421-425.
23. Padhani A.R. MRI for assessing antivascular cancer treatments. Br J Radiol 2003, 76(Spec No. 1):S60-S80.
24. Armitage P.A., Farrall A.J., Carpenter T.K., Doubal F.N., Wardlaw J.M. Use of dynamic contrast-enhanced MRI to measure subtle blood-brain barrier abnormalities. Magn Reson Imaging 2011, 29:305-314.
25. Gillies R.J., Schornack P.A., Secomb T.W., Raghunand N. Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1999, 1:197-207.
26. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
27. O'Connor J.P., Rose C.J., Waterton J.C., Carano R.A., Parker G.J., Jackson A. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res 2015, 21:249-257.
28. Checkley D., Tessier J.J., Kendrew J., Waterton J.C., Wedge S.R. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 2003, 89:1889-1895.
29. Galbraith S.M., Maxwell R.J., Lodge M.A., Tozer G.M., Wilson J., Taylor N.J., et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003, 21:2831-2842.
30. Yankeelov T.E., Lepage M., Chakravarthy A., Broome E.E., Niermann K.J., Kelley M.C., et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 2007, 25:1-13.
31. Rose C.J., Mills S.J., O'Connor J.P., Buonaccorsi G.A., Roberts C., Watson Y., et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 2009, 62:488-499.
32. Chang Y.C., Huang Y.H., Huang C.S., Chang P.K., Chen J.H., Chang R.F. Classification of breast mass lesions using model-based analysis of the characteristic kinetic curve derived from fuzzy c-means clustering. Magn Reson Imaging 2012, 30:312-322.
33. Lavini C., Verhoeff J.J., Majoie C.B., Stalpers L.J., Richel D.J., Maas M. Model-based, semiquantitative and time intensity curve shape analysis of dynamic contrast-enhanced MRI: a comparison in patients undergoing antiangiogenic treatment for recurrent glioma. J Magn Reson Imaging 2011, 34:1303-1312.
34. Berry L.R., Barck K.H., Go M.A., Ross J., Wu X., Williams S.P., et al. Quantification of viable tumor microvascular characteristics by multispectral analysis. Magn Reson Med 2008, 60:64-72.
35. Cavagna F.M., Lorusso V., Anelli P.L., Maggioni F., de Haen C. Preclinical profile and clinical potential of gadocoletic acid trisodium salt (B22956/1), a new intravascular contrast medium for MRI. Acad Radiol 2002, 9(Suppl. 2):S491-S494.
36. Rovero S., Amici A., Di Carlo E., Bei R., Nanni P., Quaglino E., et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000, 165:5133-5142.
37. Holmgren L., Ambrosino E., Birot O., Tullus C., Veitonmaki N., Levchenko T., et al. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A 2006, 103:9208-9213.
38. Ramachandran S., Calcagno C., Mani V., Robson P.M., Fayad Z.A. Registration of dynamic contrast-enhanced MRI of the common carotid artery using a fixed-frame template-based squared-difference method. J Magn Reson Imaging 2014, 39:1017.
39. Brookes J.A., Redpath T.W., Gilbert F.J., Murray A.D., Staff R.T. Accuracy of T1 measurement in dynamic contrast-enhanced breast MRI using two- and three-dimensional variable flip angle fast low-angle shot. J Magn Reson Imaging 1999, 9:163-171.
40. Liimatainen T., Sierra A., Hanson T., Sorce D.J., Yla-Herttuala S., Garwood M., et al. Glioma cell density in a rat gene therapy model gauged by water relaxation rate along a fictitious magnetic field. Magn Reson Med 2012, 67:269-277.
41. Ertas G., Gulcur H.O., Tunaci M. Improved lesion detection in MR mammography: three-dimensional segmentation, moving voxel sampling, and normalized maximum intensity-time ratio entropy. Acad Radiol 2007, 14:151-161.
42. Michoux N., Simoni P., Tombal B., Peeters F., Machiels J.P., Lecouvet F. Evaluation of DCE-MRI postprocessing techniques to assess metastatic bone marrow in patients with prostate cancer. Clin Imaging 2012, 36:308-315.
43. Faul F., Erdfelder E., Lang A.G., Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007, 39:175-191.
44. Knopp M.V., von Tengg-Kobligk H., Choyke P.L. Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther 2003, 2:419-426.
45. Arigoni M., Barutello G., Lanzardo S., Longo D., Aime S., Curcio C., et al. A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. Angiogenesis 2012, 15:305-316.
46. Preda A., Turetschek K., Daldrup H., Floyd E., Novikov V., Shames D.M., et al. The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors. Invest Radiol 2005, 40:349-354.
47. Peng S.L., Chen C.F., Liu H.L., Lui C.C., Huang Y.J., Lee T.H., et al. Analysis of parametric histogram from dynamic contrast-enhanced MRI: application in evaluating brain tumor response to radiotherapy. NMR Biomed 2013, 26:443-450.
48. Chang Y.C., Huang C.S., Liu Y.J., Chen J.H., Lu Y.S., Tseng W.Y. Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. Phys Med Biol 2004, 49:3593-3602.
49. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
50. Preda A., Novikov V., Moglich M., Turetschek K., Shames D.M., Brasch R.C., et al. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 2004, 20:865-873.
51. Ali M.M., Janic B., Babajani-Feremi A., Varma N.R., Iskander A.S., Anagli J., et al. Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PLoS One 2010, 5:e8727.
52. Fotinos-Hoyer A.K., Guermazi A., Jara H., Eckstein F., Ozonoff A., Khard H., et al. Assessment of synovitis in the osteoarthritic knee: comparison between manual segmentation, semiautomated segmentation, and semiquantitative assessment using contrast-enhanced fat-suppressed T1-weighted MRI. Magn Reson Med 2010, 64:604-609.
53. Botta M., Avedano S., Giovenzana G.B., Lombardi A., Longo D., Cassino C., et al. Relaxometric study of a series of Monoaqua Gd-III complexes of rigidified EGTA-Like chelators and their noncovalent interaction with human serum albumin. Eur J Inorg Chem 2011, 802-810.
54. Raatschen H.J., Fu Y., Brasch R.C., Pietsch H., Shames D.M., Yeh B.M. In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model. Invest Radiol 2009, 44:265-270.
55. Wilmes L.J., Pallavicini M.G., Fleming L.M., Gibbs J., Wang D., Li K.L., et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007, 25:319-327.
56. Bandini S., Curcio C., Macagno M., Quaglino E., Arigoni M., Lanzardo S., et al. Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. Oncoimmunology 2013, 2:e26137.